MedX Health Corp., a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced it has acquired the Canadian operations of 27 year old laser pioneer, Reimers & Janssen GmbH (herein after "RJ-Laser"), providing an expanded line of products, with improved product features, within MedX's existing rehab/chiropractic, dental, and acupuncture laser and light markets, as well as approved products ready for launch to Veterinarians and Dermatologists.

Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

Roche Diagnostics has purchased assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow. These assets consist of key instrumentation in the comprehensive Roche NimbleGen microarray workflow including the NimbleGen Hybridization Systems (both 4- and 12-bay models).

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

MRI (magnetic resonance imaging) scans provide extraordinarily clear images of the human body and are commonly used to diagnose a wide range of illnesses and injuries, such as Alzheimer’s disease, cancerous tumors, and torn ligaments. Analog Devices, Inc., the leading provider of data conversion technology and longtime collaborator with the medical imaging industry, today introduced a breakthrough in data conversion that gives clinicians and radiologists the superior image clarity they need to see smaller anatomical structures and abnormalities, such as breast cancer cells, than ever before.

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.